Skip to main content

Table 1 Baseline characteristics

From: Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

 

Placebo (n = 77)

Alirocumab 150 mg Q2W (n = 108)

Age, mean (SD), years

53.8 (9.4)

58.2 (10.1)

Males, %

49.4

43.5

Race, %

  

 White

84.4

88.9

 Black or African American

13.0

11.1

 Other

2.6

0

Body mass index, mean (SD), kg/m2

28.9 (4.7)

29.2 (4.6)

Lipid parameters (determined by conventional methods), mean (SD), mg/dL

  

 LDL-C

130.6 (27.5)

127.2 (25.0)

 Total cholesterol

210.5 (32.1)

208.0 (30.5)

 HDL-C

51.8 (13.8)

53.8 (15.0)

 Non-HDL-C

158.7 (30.8)

154.2 (31.3)

 Triglycerides, median (Q1:Q3)

122.5 (91.5–174.0)

123.5 (87.8–168.5)

 Apolipoprotein B

108.8 (22.8)

108.1 (23.9)

 Lipoprotein (a), median (Q1:Q3)

19.0 (6.0–77.0)

28.0 (9.0–70.0)

  1. Pooled patients from placebo and alirocumab 150 mg Q2W groups of three Phase II studies. To convert cholesterol values to mmol/L, multiply by 0.02586; to convert triglycerides to mmol/L, multiply by 0.01129
  2. Q2W every 2 weeks, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X